BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 21512758)

  • 1. Monthly administration of a novel PTH-collagen binding domain fusion protein is anabolic in mice.
    Ponnapakkam T; Katikaneni R; Miller E; Ponnapakkam A; Hirofumi S; Miyata S; Suva LJ; Sakon J; Matsushita O; Gensure RC
    Calcif Tissue Int; 2011 Jun; 88(6):511-20. PubMed ID: 21512758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A single injection of the anabolic bone agent, parathyroid hormone-collagen binding domain (PTH-CBD), results in sustained increases in bone mineral density for up to 12 months in normal female mice.
    Ponnapakkam T; Katikaneni R; Suda H; Miyata S; Matsushita O; Sakon J; Gensure RC
    Calcif Tissue Int; 2012 Sep; 91(3):196-203. PubMed ID: 22806683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infrequent delivery of a long-acting PTH-Fc fusion protein has potent anabolic effects on cortical and cancellous bone.
    Kostenuik PJ; Ferrari S; Pierroz D; Bouxsein M; Morony S; Warmington KS; Adamu S; Geng Z; Grisanti M; Shalhoub V; Martin S; Biddlecome G; Shimamoto G; Boone T; Shen V; Lacey D
    J Bone Miner Res; 2007 Oct; 22(10):1534-47. PubMed ID: 17576164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of growth hormone administration on bone mineral metabolism, PTH sensitivity and PTH secretory rhythm in postmenopausal women with established osteoporosis.
    Joseph F; Ahmad AM; Ul-Haq M; Durham BH; Whittingham P; Fraser WD; Vora JP
    J Bone Miner Res; 2008 May; 23(5):721-9. PubMed ID: 18052753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Normal epidermal growth factor receptor signaling is dispensable for bone anabolic effects of parathyroid hormone.
    Schneider MR; Dahlhoff M; Andrukhova O; Grill J; Glösmann M; Schüler C; Weber K; Wolf E; Erben RG
    Bone; 2012 Jan; 50(1):237-44. PubMed ID: 22056328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anabolic actions of PTH (1-34): use of a novel tissue engineering model to investigate temporal effects on bone.
    Pettway GJ; Schneider A; Koh AJ; Widjaja E; Morris MD; Meganck JA; Goldstein SA; McCauley LK
    Bone; 2005 Jun; 36(6):959-70. PubMed ID: 15878317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Six-month daily administration of parathyroid hormone and parathyroid hormone-related protein peptides to adult ovariectomized rats markedly enhances bone mass and biomechanical properties: a comparison of human parathyroid hormone 1-34, parathyroid hormone-related protein 1-36, and SDZ-parathyroid hormone 893.
    Stewart AF; Cain RL; Burr DB; Jacob D; Turner CH; Hock JM
    J Bone Miner Res; 2000 Aug; 15(8):1517-25. PubMed ID: 10934650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unmasking the osteoinductive effects of a G-protein-coupled receptor (GPCR) kinase (GRK) inhibitor by treatment with PTH(1-34).
    Wang L; Quarles LD; Spurney RF
    J Bone Miner Res; 2004 Oct; 19(10):1661-70. PubMed ID: 15355561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The anabolic action of intermittent PTH in combination with cathepsin K inhibitor or alendronate differs depending on the remodeling status in bone in ovariectomized mice.
    Yamane H; Sakai A; Mori T; Tanaka S; Moridera K; Nakamura T
    Bone; 2009 Jun; 44(6):1055-62. PubMed ID: 19303837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-treatment of PTH with osteoprotegerin or alendronate increases its anabolic effect on the skeleton of oophorectomized mice.
    Samadfam R; Xia Q; Goltzman D
    J Bone Miner Res; 2007 Jan; 22(1):55-63. PubMed ID: 17014384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treating osteoporosis by targeting parathyroid hormone to bone.
    Ponnapakkam T; Katikaneni R; Sakon J; Stratford R; Gensure RC
    Drug Discov Today; 2014 Mar; 19(3):204-8. PubMed ID: 23932952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ZT-031, a cyclized analog of parathyroid hormone(1-31) for the potential treatment of osteoporosis.
    Nemeth EF
    IDrugs; 2008 Nov; 11(11):827-40. PubMed ID: 18988128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accretion of bone mass and strength with parathyroid hormone prior to the onset of estrogen deficiency can provide temporary beneficial effects in skeletally mature rats.
    Shen V; Birchman R; Liang XG; Wu DD; Dempster DW; Lindsay R
    J Bone Miner Res; 1998 May; 13(5):883-90. PubMed ID: 9610753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined treatment with a beta-blocker and intermittent PTH improves bone mass and microarchitecture in ovariectomized mice.
    Pierroz DD; Bouxsein ML; Rizzoli R; Ferrari SL
    Bone; 2006 Aug; 39(2):260-7. PubMed ID: 16531131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Skeletal unloading alleviates the anabolic action of intermittent PTH(1-34) in mouse tibia in association with inhibition of PTH-induced increase in c-fos mRNA in bone marrow cells.
    Tanaka S; Sakai A; Tanaka M; Otomo H; Okimoto N; Sakata T; Nakamura T
    J Bone Miner Res; 2004 Nov; 19(11):1813-20. PubMed ID: 15476581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Skeletal effects of parathyroid hormone infusion in ovariectomized rats with or without estrogen repletion.
    Shen V; Birchman R; Wu DD; Lindsay R
    J Bone Miner Res; 2000 Apr; 15(4):740-6. PubMed ID: 10780865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Development of hPTHrP (1-36) as an anabolic therapeutic agent for osteoporosis].
    Takeuchi Y
    Clin Calcium; 2011 Jan; 21(1):28-32. PubMed ID: 21187591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intermittent PTH(1-34) does not increase union rates in open rat femoral fractures and exhibits attenuated anabolic effects compared to closed fractures.
    Tägil M; McDonald MM; Morse A; Peacock L; Mikulec K; Amanat N; Godfrey C; Little DG
    Bone; 2010 Mar; 46(3):852-9. PubMed ID: 19922821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone anabolic effects of parathyroid hormone are blunted by deletion of the Wnt antagonist secreted frizzled-related protein-1.
    Bodine PV; Seestaller-Wehr L; Kharode YP; Bex FJ; Komm BS
    J Cell Physiol; 2007 Feb; 210(2):352-7. PubMed ID: 17044082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maintenance of increased bone mass after recombinant human parathyroid hormone (1-84) with sequential zoledronate treatment in ovariectomized rats.
    Rhee Y; Won YY; Baek MH; Lim SK
    J Bone Miner Res; 2004 Jun; 19(6):931-7. PubMed ID: 15125792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.